Protect access to abortion medication

In anticipation of a Texas federal district court ruling suspending the Food and Drug Administration’s approval of mifepristone, many Alliance states began securing stockpiles of abortion medication.
Amicus Brief in Food and Drug Administration, et al., v. Alliance for Hippocratic Medicine
  • Oregon
    •
  • Oregon
    •  July 22, 2024

    Amicus Brief in Food and Drug Administration, et al., v. Alliance for Hippocratic Medicine

    Governor Kotek and 21 other governors filed an amicus brief with the U.S. Supreme Court in support of abortion rights in Food and Drug Administration, et al., v. Alliance for Hippocratic Medicine. In this brief, the Reproductive Freedom Alliance governors argued that if the Court reverses FDA approval of Mifepristone and limits access to the vital medicine, it could undermine Governors’ ability to provide adequate healthcare services and would have far-reaching implications beyond reproductive healthcare.
    Lawsuit Over Unnecessary Abortion Medication Restrictions
  • Oregon
    •
  • Oregon
    •  July 22, 2024

    Lawsuit Over Unnecessary Abortion Medication Restrictions

    As the Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration lawsuit was underway, Oregon’s Attorney General Ellen Rosenblum joined Washington State’s Attorney General Bob Ferguson in co-leading a multi-state lawsuit against the FDA to protect enhanced access to mifepristone. The outcome of this lawsuit was Judge Thomas Rice’s decision barring the FDA from making any changes that could reduce the availability of mifepristone in the 17 states that signed on to the lawsuit.
    Mifepristone Stockpile
  • Oregon
    •
  • Oregon
    •  July 22, 2024

    Mifepristone Stockpile

    In response to the Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration’s lawsuit challenging the FDA’s approval of the medication abortion drug mifepristone, Oregon secured a three-year supply of the drug. This stockpile ensures that patients seeking abortion services in Oregon will continue to have access to a safe and effective method of abortion. Oregon also developed a plan to distribute its supply of mifepristone equitably to eligible prescribers.
    Oregon Health Authority’s Reproductive Health Program
  • Oregon
    •
  • Oregon
    •

    Oregon Health Authority’s Reproductive Health Program

    The Oregon Health Authority’s Reproductive Health Program has leveraged diverse funding streams to create more efficient and flexible funding sources for Oregon’s network of publicly funded reproductive health clinics, including new infrastructure grants using Title X funds to bolster access to reproductive health services.
    Reproductive Health Infrastructure Investments
  • Oregon
    •
  • Oregon
    •

    Reproductive Health Infrastructure Investments

    Oregon allocated $3.4 million dollars to the Oregon Health Authority (OHA) as part of Public Health Modernization to support reproductive health infrastructure development. This funding created a state-wide abortion access website, provided OHA-wide reproductive health services reimbursement rate revisions and alignment, and provided infrastructure grants to service providers across the state.
    Amicus Brief in Food and Drug Administration, et al., v. Alliance for Hippocratic Medicine
  • New York
    •
  • New York
    •  July 22, 2024

    Amicus Brief in Food and Drug Administration, et al., v. Alliance for Hippocratic Medicine

    Governor Hochul and 21 other governors filed an amicus brief with the U.S. Supreme Court in support of abortion rights in Food and Drug Administration, et al., v. Alliance for Hippocratic Medicine. In this brief, the Reproductive Freedom Alliance governors argued that if the Court reverses FDA approval of Mifepristone and limits access to the vital medicine, it could undermine Governors’ ability to provide adequate healthcare services and would have far-reaching implications beyond reproductive healthcare.
    Funding to Support Access to Care
  • New York
    •
  • New York
    •  July 22, 2024

    Funding to Support Access to Care

    Governor Hochul announced that if the abortion medication Mifepristone is taken off the market, the State will commit up to an additional $20 million to providers to support access to other methods of care.
    Misoprostol Stockpile
  • New York
    •
  • New York
    •  July 22, 2024

    Misoprostol Stockpile

    In response to the SCOTUS decision on Dobbs, the New York State Department of Health under the Governor’s direction, purchased Misoprostol in order to stockpile 150,000 doses, a five-year supply, in order to meet anticipated needs and protect access.
    Chapter 129 of the Laws of 2023
  • New York
    •
  • New York
    •  July 22, 2024

    Chapter 129 of the Laws of 2023

    This law ensures that every student enrolled in a SUNY or CUNY college has access to medication abortion on campus.
    Fiscal Year 2024 Budget
  • New York
    •
  • New York
    •  July 22, 2024

    Fiscal Year 2024 Budget

    Included in Governor Hochul’s FY 2024 Budget were increased Medicaid reimbursement rates to boost New York abortion access, additional data protections for patients seeking reproductive health care, requirements for private insurers to cover medication abortion when prescribed off-label for abortion, and $100.7 million in newly allocated funding to support abortion providers and reproductive health care.